Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.45 |
| ▸ | LAP3 | P28838 | 2/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697104 | 0.74 | FDPS (0.47) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL16697383 | 0.72 | FDPS (0.47) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL15282992 | 0.69 | GPR84 (0.41) | FDPSCA1ACE2 | |
| SCHEMBL17363778 | 0.69 | GPR84 (0.47) | CA1ACE2 | |
| SCHEMBL9164732 | 0.68 | FDPS (0.52) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| Phosphoric Acid SCHEMBL11332263 | 0.68 | FDPS (0.53) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL29218658 | 0.67 | GPR84 (0.46) | CA1ACE2 | |
| SCHEMBL14938306 | 0.67 | FDPS (0.42) | FDPSLAP3FNTAFNTBS1PR2 | |
| SCHEMBL13515110 | 0.66 | FFAR4 (0.47) | — | |
| SCHEMBL16697204 | 0.66 | FDPS (0.34) | FDPSLAP3CA1SMPD1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934604-B2 | Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-03-02 | — | — | US | disclosed |
| US-10450629-B2 | Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method | COMMISSARIAT A L+ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180142321-A1 | USE OF NOVEL COMPOUNDS FOR SELECTIVELY EXTRACTING RARE EARTHS FROM AQUEOUS SOLUTIONS INCLUDING PHOSPHORIC ACID AND ASSOCIATED EXTRACTION METHOD | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450629-B2 | Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method | HRH3, ALK, H1-0 | FDPS 2779/4885LAP3 2965/4885FNTA 3186/4885 |
| US-10934604-B2 | Use of novel compounds for selectively extracting rare earths from aqueous solutions including phosphoric acid and associated extraction method | HRH3, ALK, H1-0 | FDPS 2779/4885LAP3 2965/4885FNTA 3186/4885 |
| US-20180142321-A1 | USE OF NOVEL COMPOUNDS FOR SELECTIVELY EXTRACTING RARE EARTHS FROM AQUEOUS SOLUTIONS INCLUDING PHOSPHORIC ACID AND ASSOCIATED EXTRACTION METHOD | HRH3, ALK, H1-0 | FDPS 2779/4885LAP3 2965/4885FNTA 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.